| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm focused on developing innovative therapies for disorders of the central nervous system and critical lung diseases. Its product portfolio features ZYESAMI, an experimental medication that has successfully completed Phase IIb/III clinical trials for treating respiratory failure associated with COVID-19. Additionally, the company is advancing NRX-100 and NRX-101, a pair of oral therapeutics designed to address bipolar depression, specifically in patients exhibiting acute or …
Over the last 12 months, insiders at NRx Pharmaceuticals, Inc. have bought $0 and sold $0 worth of NRx Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at NRx Pharmaceuticals, Inc. have bought $288,851 and sold $761,190 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 40,000 shares for transaction amount of $46,800 was made by Javitt Jonathan C (Chairman and Chief Scientist) on 2024‑12‑17.
| 2024-12-17 | Javitt Jonathan C | Chairman and Chief Scientist | 40,000 0.2543% | $1.17 | $46,800 | +62.50% | ||
| 2023-08-30 | Hurvitz Chaim | director | 70,000 0.0777% | $0.29 | $20,125 | +1.74% | ||
| 2023-08-30 | Gorovitz Aaron | director | 35,000 0.0432% | $0.32 | $11,197 | +1.74% | ||
| 2023-08-23 | Javitt Jonathan C | Chief Scientist | 100,000 0.135% | $0.33 | $33,000 | +14.44% | ||
| 2023-08-22 | Javitt Jonathan C | Chief Scientist | 200,000 0.2614% | $0.32 | $64,400 | +7.62% | ||
| 2022-12-16 | Willard Stephen H | CHIEF EXECUTIVE OFFICER | 50,000 0.0773% | $1.17 | $58,500 | -55.52% | ||
| 2022-12-16 | VAN VOORHEES SETH | CHIEF FINANCIAL OFFICER | 30,000 0.0436% | $1.10 | $33,000 | -55.52% | ||
| 2022-12-07 | Sale | Javitt Jonathan C | director | 400,000 0.4224% | $1.00 | $400,000 | -63.19% | |
| 2022-11-30 | Sale | Javitt Daniel C. | director | 8,441 0.0134% | $1.50 | $12,700 | -60.42% | |
| 2022-11-29 | Sale | Javitt Daniel C. | director | 13,730 0.0228% | $1.50 | $20,651 | -58.70% | |
| 2022-11-28 | Flynn Patrick John | director | 6,750 0.0102% | $1.25 | $8,413 | -54.32% | ||
| 2022-11-25 | VAN VOORHEES SETH | CHIEF FINANCIAL OFFICER | 16,337 0.0241% | $1.11 | $18,215 | -49.65% | ||
| 2022-11-18 | Hurvitz Chaim | director | 40,408 0.0593% | $1.10 | $44,449 | -47.89% | ||
| 2022-11-17 | Sale | Javitt Daniel C. | director | 33,018 0.0433% | $1.05 | $34,745 | -51.07% | |
| 2022-11-17 | Hurvitz Chaim | director | 171,780 0.2312% | $1.08 | $185,522 | -51.07% | ||
| 2022-11-16 | Sale | Javitt Daniel C. | director | 133,719 0.1975% | $1.02 | $136,393 | -42.86% | |
| 2022-11-16 | Hurvitz Chaim | director | 287,812 0.4126% | $0.99 | $284,934 | -42.86% | ||
| 2022-11-11 | Sale | Javitt Daniel C. | director | 49,200 0.0753% | $1.01 | $49,510 | -38.75% | |
| 2022-07-29 | Sale | Javitt Daniel C. | 784,063 1.5019% | $1.01 | $791,433 | -6.94% | ||
| 2022-06-03 | Sale | Javitt Daniel C. | 115,657 0.1594% | $0.67 | $76,947 | +0.54% |
| Hurvitz Chaim | director | 570000 1.3165% | $1.28M | 4 | 0 | <0.0001% |
| ACKERMAN RICHARD | President and CEO | 225000 0.5197% | $504,000.00 | 1 | 1 | +3.13% |
| Gorovitz Aaron | director | 105000 0.2425% | $235,200.00 | 1 | 0 | +1.74% |
| Javitt Jonathan C | Chairman and Chief Scientist | 84634 0.1955% | $189,580.16 | 4 | 1 | +28.39% |
| Willard Stephen H | CHIEF EXECUTIVE OFFICER | 50000 0.1155% | $112,000.00 | 1 | 0 | <0.0001% |
| VAN VOORHEES SETH | CHIEF FINANCIAL OFFICER | 46337 0.107% | $103,794.88 | 2 | 0 | <0.0001% |
| Flynn Patrick John | director | 40209 0.0929% | $90,068.16 | 1 | 0 | <0.0001% |
$5,552,811 | 165 | 5.84% | $106.2M | |
$1,701,941 | 56 | 17.58% | $93.09M | |
$66,137,559 | 49 | 6.29% | $89.66M | |
$77,146,704 | 43 | 13.28% | $93.12M | |
$63,049,419 | 31 | 2.87% | $107.27M |
| Increased Positions | 14 | +48.28% | 2M | +46.53% |
| Decreased Positions | 12 | -41.38% | 562,141 | -14.21% |
| New Positions | 7 | New | 556,115 | New |
| Sold Out Positions | 3 | Sold Out | 317,361 | Sold Out |
| Total Postitions | 31 | +6.9% | 5M | +32.32% |
| Anson Funds Management Lp | $5,306.00 | 6.75% | 2.03M | +420,129 | +26.18% | 2025-09-30 |
| Vanguard Group Inc | $1,402.00 | 1.78% | 534,956 | +82,781 | +18.31% | 2025-09-30 |
| Advisorshares Investments Llc | $896.00 | 1.14% | 342,136 | +78,339 | +29.7% | 2025-09-30 |
| Marshall Wace, Llp | $496.00 | 0.63% | 189,136 | +155,752 | +466.55% | 2025-09-30 |
| Geode Capital Management, Llc | $487.00 | 0.62% | 185,862 | +13,607 | +7.9% | 2025-09-30 |
| Ubs Group Ag | $400.00 | 0.51% | 152,848 | +31,240 | +25.69% | 2025-09-30 |
| Renaissance Technologies Llc | $336.00 | 0.43% | 128,175 | +128,175 | New | 2025-09-30 |
| State Street Corp | $200.00 | 0.25% | 76,284 | +25,200 | +49.33% | 2025-09-30 |
| Jane Street Group, Llc | $192.00 | 0.25% | 73,399 | +73,399 | New | 2025-09-30 |
| Blackrock, Inc. | $171.00 | 0.22% | 65,412 | +1,012 | +1.57% | 2025-09-30 |